Activity Information

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Consultants and MD Media, Inc. CME Consultants is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
CME Consultants designates this enduring material for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience
This activity is geared to meet the educational requirements of Healthcare Providers, especially those dealing with mental health, prescribers, counselors, etc.

Core Competencies
This activity encompasses the following desirable physician attributes: Patient Care & Procedural Skills, Medical Knowledge, Professionalism, Practice-Based Learning & Improvement, and Systems-Based Practice.

Format
The presentational method for this activity is Lecture.

Desired Outcomes

At the conclusion of the activity, participants should be able to:

“MDMA: Promise in PTSD and Beyond”

  • Recognize which conditions have been shown to respond to MDMA-assisted psychotherapy
  • Explain the pharmacological mechanisms of action of MDMA
  • Implement and create the ideal office/space environment for MDMA-psychotherapy session
  • Advise patients regarding the safety risks, side effects, and contraindications for MDMA-assisted therapy
  • Identify the medications and supplements that should not be combined with MDMA
  • Describe MDMA’s legal history and its current DEA scheduling

“Mechanisms of Action: What We Know About the Classic Psychedelics”

  • Discuss the cultural and legal history of psychedelic medicine in the United States
  • Evaluate the available safety and efficacy data on the pharmacological mechanisms of action and pharmacokinetics of various “classic” psychedelics
  • Summarize some of the recent clinical trials and other research done on each of these substances
  • Improve the treatment of mood disorders by differentiating between how psychedelic medicines and conventional anti-depressant medications work on the brain
  • Explain the theory of the default mode network and its effects of mood and behavior
  • Analyze the elements of the mystical experience and explain their importance in the context of psychological recovery

“Ketamine for Depression and Mood Disorders: Microdoses, Psychedelic Doses, and Everything In Between”

  • Recognize which conditions have been shown to respond to the off-label use of ketamine in recent clinical trials
  • Explain the pharmacological differences between S- R- and racemic ketamine
  • Summarize which uses of ketamine are currently FDA approved, and for what indications
  • Discuss the safety risks, side effects, and contraindications for ketamine
  • Incorporate new clinical data on the new routes of administration and dosage protocols by which ketamine may be administered for psychological treatment purposes
  • Determine which patients may be good candidates for ketamine treatment
  • Summarize the current theory on ketamine’s pharmacological mechanism of action in the treatment of mood disorders

“Psychedelic Counseling: The Foundations of Therapeutic ‘Trip Sitting’”

  • Explain the common causes of a “bad trip,” and how to prevent them
  • Implement proper set and setting in sessions, and describe their importance within the psychotherapeutic context of psychedelic use
  • Develop basic strategies in non-directive therapy
  • Summarize the theory of Internal Family Systems (IFS) therapy
  • Support a patient experiencing a challenging psychedelic experience
  • Incorporate “integration” into the healing experience and articulate its importance within the context of psychedelic therapy

“Microdosing Psychedelics: What We Know and Don’t”

  • Summarize the challenges and roadblocks of conducting double-blind, placebo-controlled trials on psychedelic microdosing
  • Define psychedelic microdosing, and differentiate it from medium or macrodosing
  • Evaluate and new and emerging data regarding the theorized mechanism of action of psychedelic microdoses’ effects on mood and behavior
  • Discuss the safety risks, side effects, and contraindications for microdosing
  • Explain the drug-drug interactions of psychedelic microdoses with common Rx medications
  • Identify the patients/conditions that may potentially respond well to psychedelic microdosing

“The Psychedelic Treatment of Addiction: LSD, Psilocybin, Ayahuasca, Iboga”

  • Evaluate new and emerging therapies to determine how they may be integrated into the treatment of various substance use disorders
  • Analyze the elements of the mystical experiences and explain their importance in the context of addiction recovery
  • Summarize some of the recent clinical trials and other research done on each of these substances
  • List the differences between how psychedelic medicines and conventional medications treat addiction
  • Explain the differences between LSD, Psilocybin, Ayahuasca, and Ibogaine with respect to their cultural origins
  • Implement protocols for screening for contraindications/cautions in using these substances in the treatment of addiction

Disclosure Statements

Commercial Support
There is no commercial support for this activity.

Planners
The planners of this activity have nothing to disclose.

Faculty
Erica Zelfand, ND has nothing to disclose. The course content has been peer-reviewed for content validity and found to be evidenced-based, fair, balanced, and free from commercial bias.

Launch Date
March 10, 2021

Expiration Date
March 10, 2023